To address pharmaceutical supply challenges in Nigeria, the Federal Government has signed a $32 million agreement for an intravenous (IV) fluids production facility in the Caribbean nation of Barbados, raising questions about how the investment will benefit the country’s healthcare sector, particularly its efforts to reduce dependence on imported medical products.
The initiative, involving Nigerian pharmaceutical manufacturer AMA Medical Manufacturing, Barbados Pharmaceutical Inc. (BPI) and the African Export-Import Bank (Afreximbank), is expected to commence production in 2029, with an initial annual capacity of 12 million units.
The project is expected to strengthen pharmaceutical supply chains, improve regional health security and promote industrial cooperation between Africa and the Caribbean.
However, as the Federal Government celebrates the initiative, the question in the minds of many Nigerians is whether an investment in pharmaceutical production outside the country will address the supply challenges confronting the domestic pharmaceutical industry.
This concern is particularly important given Nigeria’s longstanding dependence on imported medicines and pharmaceutical raw materials, despite successive government policies aimed at encouraging local manufacturing.
The project featured prominently at the 2026 Commonwealth Heads of Government Meeting (CHOGM) in St John’s, Antigua and Barbuda. It represents a significant attempt to translate longstanding diplomatic and historical relations between Africa and the Caribbean into tangible industrial investments.
The partnership is being championed by the governments of Nigeria and Barbados, with support from the World Trade Organisation (WTO), as part of a broader strategy to expand pharmaceutical manufacturing capacity, create skilled employment and reduce dependence on imported essential medical products.
Under the proposed arrangement, AMA Medical Manufacturing will contribute Nigerian pharmaceutical manufacturing expertise, while BPI will facilitate the development of production capacity in Barbados to serve Caribbean and international markets.
The partners also envisage expanding production beyond IV fluids to other pharmaceutical products, subject to technical, commercial and regulatory assessments.
Two preliminary agreements underpin the initiative: a memorandum of understanding between BPI and AMA Medical Manufacturing, and a project preparation facility term sheet between AMA and Afreximbank.
The financing framework being developed by Afreximbank will combine project preparation assistance, senior debt, working capital and risk-bearing instruments to support the establishment and eventual operation of the facility.
Secretary to the Government of the Federation (SGF), Senator George Akume, described the partnership as another demonstration of Nigeria’s determination to deepen economic relations with Caribbean countries through productive industrial investments.
Akume said the collaboration would provide opportunities for Nigerian manufacturers to expand into new markets while promoting technology transfer, healthcare production and employment generation.
He said: “Nigeria’s partnership with Barbados reflects our commitment to deepening economic cooperation between Africa and the Caribbean through practical industrial initiatives.
“By bringing together Nigerian manufacturing expertise and Caribbean investment opportunities, we can strengthen healthcare production, expand trade and create new pathways for technology exchange and skills development, amplifying the potential of South-South Cooperation.”
Barbados Prime Minister, Mia Mottley, described the partnership as a milestone in efforts by African and Caribbean nations to take greater responsibility for their economic development and healthcare security.
According to her, the investment demonstrates that the size of a country should not determine the scale of its industrial ambitions.
Mottley said: “Barbados may be a small island state, but our ambitions for our people and our region are not small.
“This partnership represents the determination of African and Caribbean nations to build productive capacity, strengthen our health security and create opportunities that will endure for generations.
“It is also a powerful expression of what becomes possible when we recognise our shared history and choose to shape our future together.”
Director-General of the World Trade Organisation, Dr Ngozi Okonjo-Iweala, said the initiative was a practical demonstration of how international trade and investment could strengthen healthcare systems by diversifying pharmaceutical production across developing economies.
Okonjo-Iweala stated that the COVID-19 pandemic exposed serious vulnerabilities in global medical supply chains, particularly the concentration of essential pharmaceutical manufacturing in a limited number of countries.
She said expanding production capacity in Africa and the Caribbean would help address those weaknesses while creating fresh opportunities for industrial development and employment.
Her words: “We are delighted to see this partnership taking shape, and to have been part of the journey. This is re-globalisation in action.
“The COVID-19 pandemic exposed the risks of concentrating essential medical production in too few countries.
“This partnership demonstrates how trade and investment can help expand production, connect the capabilities of Africa and the Caribbean, and deepen South-South and triangular cooperation.
“By expanding pharmaceutical manufacturing, it strengthens supply chain resilience while creating new opportunities for growth, development and industrial capacity.”
The WTO Secretariat has provided initial support for the project, particularly in promoting the regulatory frameworks necessary to diversify the production of essential medical products and strengthen trade between developing economies.
Senior Executive Vice-President of Afreximbank, Denys Denya, said the investment would consolidate the bank’s expanding economic relationship with Caribbean countries.
He recalled that the institution’s engagement with the region gained momentum during the COVID-19 pandemic, when African and Caribbean partners collaborated to facilitate access to vaccines.
Denya explained that the proposed pharmaceutical facility would build on that experience by combining Nigerian manufacturing capabilities with Caribbean investment opportunities.
Nigeria’s pharmaceutical supply challenge
The significance of the partnership becomes clearer when examined against Nigeria’s pharmaceutical manufacturing challenges.
Despite having a sizeable pharmaceutical market and an established base of local manufacturers, the country continues to depend heavily on imported medicines and pharmaceutical inputs.
According to the World Health Organisation’s African Health Observatory Platform, Nigeria has about 150 local pharmaceutical manufacturing companies, but they meet only about 30 per cent of the country’s medical product needs. This leaves the country exposed to international supply disruptions, exchange rate movements and rising import costs.
The National Agency for Food and Drug Administration and Control (NAFDAC), however, reported in October 2025 that Nigeria’s dependence on imported medicines had declined from 70 per cent to 60 per cent, indicating some progress in domestic manufacturing.
Nevertheless, the sector continues to face significant constraints, including inadequate infrastructure, high production costs, limited access to affordable financing and dependence on imported active pharmaceutical ingredients.
A July 2026 analysis by KPMG also identified the country’s dependence on imported pharmaceutical ingredients and excipients, with more than 90 per cent of these inputs sourced externally, as a major weakness affecting the industry’s competitiveness.
These challenges have implications for the availability and affordability of medicines, particularly when foreign exchange pressures or disruptions in international supply chains affect importation.
The Federal Government has introduced several measures to encourage local production, including incentives for pharmaceutical manufacturers and the Presidential Initiative on Unlocking the Healthcare Value Chain, which seeks to increase domestic production of essential medicines and medical devices to 70 per cent by 2030.
The proposed Barbados investment could complement these efforts by giving Nigerian manufacturers access to additional markets, investment opportunities and international manufacturing partnerships.
Will Nigerians benefit directly?
However, the location and intended market of the proposed facility raise important questions about its immediate contribution to Nigeria’s pharmaceutical supply.
Unlike an investment in a domestic manufacturing plant, the Barbados facility is primarily designed to serve the Caribbean Community (CARICOM) and other international markets.
Its initial production capacity of 12 million IV fluid units annually could strengthen the supply of essential medical products in the Caribbean, but the extent to which Nigerian hospitals and pharmaceutical distributors will benefit remains unclear.
This distinction is important because Nigeria’s pharmaceutical supply problem cannot be addressed simply by increasing the manufacturing capacity of Nigerian-owned companies abroad. The country also needs more production facilities within its borders, stronger domestic supply chains and improved access to locally manufactured medicines.
There is, however, an existing industrial foundation upon which the partnership can build. The Nigerian Investment Promotion Commission reported in May 2026 that AMA Medical Manufacturing operates an IV fluid plant in Kaduna State, equipped with advanced European aseptic form-fill-seal technology.
The company’s experience in Nigeria could provide the technical foundation for its expansion into the Caribbean market while demonstrating the capacity of Nigerian pharmaceutical manufacturers to compete internationally.
The development also presents an opportunity for technology exchange, skills development and access to markets that may otherwise be difficult for Nigerian manufacturers to penetrate.
For Afreximbank, the investment represents another dimension of its efforts to strengthen economic relations between Africa and the Caribbean, particularly in strategic sectors such as healthcare, manufacturing and trade.
Nevertheless, the proposed facility must still pass through important implementation stages. Project preparation, financing arrangements, technical assessments, regulatory approvals and construction will determine whether the 2029 production target can be achieved.
The success of the partnership will therefore depend not only on the agreements signed but also on the ability of the participating institutions to translate their commitments into a commercially viable manufacturing operation.
Ultimately, the Barbados project offers Nigerian pharmaceutical manufacturers an opportunity to expand beyond the domestic market and establish a stronger presence in international supply chains.
But for millions of Nigerians grappling with the rising cost of healthcare and medicines, the more immediate expectation is increased domestic production, reliable availability of essential drugs and reduced dependence on imported medical products.
The partnership may strengthen Nigeria’s pharmaceutical industry through international expansion and industrial cooperation. Whether it will significantly ease the country’s own pharmaceutical supply challenges, however, will depend on how effectively the Federal Government combines such overseas investments with sustained support for manufacturing within Nigeria.
){kind=link}